Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Department of Biological, Geological and Environmental Sciences, Laboratory of Molecular Anthropology & Centre for Genome Biology, University of Bologna, Bologna, Italy.
Sci Rep. 2019 Jan 24;9(1):753. doi: 10.1038/s41598-018-37277-0.
The pathogenesis of idiopathic and heritable forms of pulmonary arterial hypertension is still not completely understood, even though several causative genes have been proposed, so that a third of patients remains genetically unresolved. Here we applied a multistep approach to extend identification of the genetic bases of such a disease by searching for novel candidate genes/pathways. Twenty-eight patients belonging to 18 families were screened for BMPR2 mutations and BMPR2-negative samples were tested for 12 additional candidate genes by means of a specific massive parallel sequencing-based assay. Finally, whole exome sequencing was performed on four patients showing no mutations at known disease genes, as well as on their unaffected parents. In addition to EIF2AK4, which has been already suggested to be associated with pulmonary veno-occlusive disease, we identified the novel candidate genes ATP13A3, CD248, EFCAB4B, involved in lung vascular remodeling that represent reliable drivers contributing to the disease according to their biological functions/inheritance patterns. Therefore, our results suggest that combining gene panel and whole exome sequencing provides new insights useful for the genetic diagnosis of familial and idiopathic pulmonary arterial hypertension, as well as for the identification of biological pathways that will be potentially targeted by new therapeutic strategies.
特发性和遗传性肺动脉高压的发病机制尚未完全阐明,尽管已经提出了几个致病基因,因此仍有三分之一的患者的遗传原因尚未确定。在这里,我们应用多步骤方法,通过寻找新的候选基因/途径,来扩展对这种疾病遗传基础的鉴定。对 18 个家族的 28 名患者进行 BMPR2 突变筛查,BMPR2 阴性样本通过特定的大规模平行测序检测 12 个额外的候选基因。最后,对四个在已知疾病基因上未发现突变的患者及其未受影响的父母进行全外显子组测序。除了已经与肺静脉闭塞性疾病相关的 EIF2AK4 外,我们还鉴定了新的候选基因 ATP13A3、CD248、EFCAB4B,它们参与肺血管重塑,根据其生物学功能/遗传模式,这些基因是导致疾病的可靠驱动基因。因此,我们的结果表明,联合基因panel 和全外显子组测序为家族性和特发性肺动脉高压的遗传诊断以及为潜在的新治疗策略提供了新的有价值的生物途径提供了新的见解。